Tet2 age associated somatic mutations impair platelet function and enhance thrombosis
Description: Megakaryocyte (MK) and platelets alterations are associated with increased thrombotic risk. MKs are rare, large, hematopoietic cells that produce platelets and regulate of bone marrow homeostasis. Altered megakaryopoiesis and platelets reactivity is a hallmark of aging and is associated with cardiovascular complications and thrombotic events. Although platelets are important drivers of thrombosis, patient responses to platelet therapies are heterogenous and conflicting. Thus, it is critical to determine if certain pre-existing conditions underlie the broad range of platelet responses clinically observed and if these conditions can stratify individuals who are at risk of developing inflammatory platelet responses or more severe disease phenotypes. Recent studies reveal that increased cardiovascular risk is accompanied by the accumulation of somatic mutations (DNA alterations acquired after birth) in hematopoietic stem cells and their differentiated progeny. This challenges the textbook notion that all cells within one person have identical DNA and opens up several questions about the significance of these changes. These mutations represent a risk state known as clonal hematopoiesis of indeterminate potential (CHIP). CHIP presents as somatic mosaicism in the blood, arising from clonal expansion of hematopoietic cells harboring genetic variations. My preliminary studies have uncovered significant functional and phenotypic changes in MKs harboring Tet2 loss of function CHIP mutations and have observed alterations to platelets as a consequence of these mutations. The long-term goal is to develop preventative and effective interventions for CHIP carriers with elevated thrombosis risk. This fundamental information will be therapeutically harnessed to rejuvenate hemostatic function, reduce vascular complications, and diminish thrombotic disease.
Funder: American Heart Association
Amount: $81,690
Funding type: training
Funder scheme: Diversity Supplement
Start date: 2025-07-01
End date: 2026-06-30
Investigator: Virginia Camacho (lead)
Institution: Boston Children's Hospital
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 2
Funder award ID: 25DIVSUP1476419
OpenAlex ID: G3432355955
